Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing frontline therapy of CLL based on clinical and biological factors.

Hematology. American Society of Hematology. Education Program - 8 Dec 2017

Fischer Kirsten, Hallek Michael

Abstract excerpt

The heterogeneity of the clinical course of chronic lymphocytic leukemia (CLL) ranges from an indolent course, where patients do not require therapy for many years, to a very aggressive disease, where treatment is required soon after diagnosis and relapses may occur early. The improved tools for prognostication allow predicting the outcome of patients with increasing reliability. Some markers also allow selecting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Age Factors
Share to Algorithms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta 2-Microglobulin

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-bcl-2

Source

Open in PubMed Open full text

Identifiers

PMID: 29222276
DOI: 10.1182/asheducation-2017.1.338
PMCID: PMC6142543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing frontline therapy of CLL based on clinical and biological factors.PMID 29222276Read ↗

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic StrategiesSemantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.Semantic proximity Read ↗

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemiaSemantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Semantic proximity Read ↗

Prognostication in chronic lymphocytic leukemia.Semantic proximity Read ↗

Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity Read ↗

Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.